• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    BioSig Technologies, Inc. Appoints Medical Device Industry Leader to its Board of Directors

    9/21/21 10:30:00 AM ET
    $BSGM
    $BSX
    $NSPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $BSGM alert in real time by email

    Westport, CT, Sept. 21, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced the appointment of James J. Barry, Ph.D. as an Independent Director to its Board of Directors.

    

    Dr. Barry has more than 30 years of experience in the medical device industry as an executive and corporate board director.  He is currently the Principal Owner at Convergent Biomedical Group LLC., a company providing advisory services to the life sciences industry. Prior to Convergent, Dr. Barry was President and CEO at InspireMD, Inc. (NASDAQ:NSPR) and platform technology company, Arsenal Medical.  Dr. Barry spent the majority of his career at Boston Scientific (NYSE:BSX) with increasing roles of responsibility culminating as Sr. Vice President of Corporate Technology. While at Boston Scientific, Dr. Barry led the development and launch of the TAXUS drug-eluting coronary stent that achieved annual sales exceeding $3 billion.

    Dr. Barry is the author of multiple peer-reviewed publications and holds more than 40 U.S. and international patents. He holds a Ph.D. in Biochemistry from the University of Massachusetts-Lowell and a B.A. in Chemistry from St. Anselm College.

    "I have always viewed the electrophysiology field as a tremendous opportunity given the burden heart rhythm disorders have on the healthcare system.  It is a space that can benefit greatly from innovation, and I am impressed with the PURE EP(tm) system which appears to be a meaningful advance in signal detection and should have a positive impact on procedure time and cost. I look forward to working with the BioSig Board and the management team to leverage my experience and executive leadership to deliver on the strategic expansion of the PURE EP(tm) system and the company's many pipeline opportunities," commented Dr. Barry.

    "Jim's accomplishments in the medical device sector are second-to-none, and we are thrilled that he can join us as our new Independent Director. Our mission is to empower physicians to make better procedural decisions through more advanced technological solutions, and Jim's industry expertise is perfectly aligned with our passion for innovation. We look forward to learning from Jim as we continue to expand our commercial roll-out," commented Kenneth L. Londoner, Chairman, and CEO of BioSig Technologies, Inc.

    The PURE EP(tm) is an FDA 510(k) cleared non-invasive class II device that aims to drive procedural efficiency and efficacy in cardiac electrophysiology. To date, over 60 physicians have completed over 1300 patient cases with the PURE EP(tm) System across twelve clinical sites.

    The Company recently completed its first multi-centered, prospective clinical trial and presented preliminary clinical data during the annual Heart Rhythm 2021 convention in July in Boston, MA.

    The Company is in a focused commercial launch of the PURE EP(tm) System in the Northeast, Texas, and Florida and is in regular use in some of the country's leading centers of excellence, including the Mayo Clinic in Rochester, MN, and St. David's Medical Center in Austin, TX. 

    About BioSig Technologies

    BioSig Technologies is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals (www.biosig.com).

    The Company's first product, PURE EP(tm) System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording, and storing electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory.

    Forward-looking Statements

    This press release contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward- looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) the geographic, social and economic impact of COVID-19 on our ability to conduct our business and raise capital in the future when needed, (ii) our inability to manufacture our products and product candidates on a commercial scale on our own, or in collaboration with third parties; (iii) difficulties in obtaining financing on commercially reasonable terms; (iv) changes in the size and nature of our competition; (v) loss of one or more key executives or scientists; and (vi) difficulties in securing regulatory approval to market our products and product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.



    Andrew Ballou
    BioSig Technologies, Inc. 
    Vice President, Investor Relations 
    54 Wilton Road, 2nd floor
    Westport, CT 06880
    [email protected]
    203-409-5444, x133
    
    

    Primary Logo

    Get the next $BSGM alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $BSGM
    $BSX
    $NSPR

    CompanyDatePrice TargetRatingAnalyst
    Boston Scientific Corporation
    $BSX
    6/16/2025$118.00Outperform
    Leerink Partners
    Boston Scientific Corporation
    $BSX
    4/16/2025$113.00Hold → Buy
    Needham
    Boston Scientific Corporation
    $BSX
    1/10/2025$108.00Hold → Buy
    Deutsche Bank
    Boston Scientific Corporation
    $BSX
    10/18/2024Buy → Hold
    Needham
    Boston Scientific Corporation
    $BSX
    5/30/2024$90.00Buy
    Goldman
    Boston Scientific Corporation
    $BSX
    2/1/2024$65.00 → $80.00Neutral → Buy
    Mizuho
    Boston Scientific Corporation
    $BSX
    7/19/2023$59.00Outperform
    Robert W. Baird
    Boston Scientific Corporation
    $BSX
    6/30/2023$64.00Buy
    CL King
    More analyst ratings

    $BSGM
    $BSX
    $NSPR
    SEC Filings

    See more
    • SEC Form SCHEDULE 13G filed by BioSig Technologies Inc.

      SCHEDULE 13G - BioSig Technologies, Inc. (0001530766) (Subject)

      7/25/25 3:18:44 PM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form PRE 14A filed by BioSig Technologies Inc.

      PRE 14A - BioSig Technologies, Inc. (0001530766) (Filer)

      7/24/25 5:00:38 PM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Boston Scientific Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - BOSTON SCIENTIFIC CORP (0000885725) (Filer)

      7/23/25 6:32:54 AM ET
      $BSX
      Medical/Dental Instruments
      Health Care

    $BSGM
    $BSX
    $NSPR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Leerink Partners initiated coverage on Boston Scientific with a new price target

      Leerink Partners initiated coverage of Boston Scientific with a rating of Outperform and set a new price target of $118.00

      6/16/25 7:46:14 AM ET
      $BSX
      Medical/Dental Instruments
      Health Care
    • Boston Scientific upgraded by Needham with a new price target

      Needham upgraded Boston Scientific from Hold to Buy and set a new price target of $113.00

      4/16/25 9:01:10 AM ET
      $BSX
      Medical/Dental Instruments
      Health Care
    • Boston Scientific upgraded by Deutsche Bank with a new price target

      Deutsche Bank upgraded Boston Scientific from Hold to Buy and set a new price target of $108.00

      1/10/25 8:51:50 AM ET
      $BSX
      Medical/Dental Instruments
      Health Care

    $BSGM
    $BSX
    $NSPR
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • March 1, 2024 - FDA Roundup: March 1, 2024

      For Immediate Release: March 01, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA issued a letter of enforcement discretion for certain qualified health claims regarding the consumption of yogurt and the reduced risk of type 2 diabetes. The letter states that the FDA does not intend to object to the use of these claims, provide

      3/1/24 4:00:21 PM ET
      $BSX
      Medical/Dental Instruments
      Health Care

    $BSGM
    $BSX
    $NSPR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Boston Scientific announces results for second quarter 2025

      MARLBOROUGH, Mass., July 23, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $5.061 billion during the second quarter of 2025, growing 22.8 percent on a reported basis, 21.6 percent on an operational1 basis and 17.4 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $797 million or $0.53 per share (EPS), compared to $324 million or $0.22 per share a year ago, and achieved adjusted3 EPS of $0.75 for the period, compared to $0.62 a year ago.

      7/23/25 6:30:00 AM ET
      $BSX
      Medical/Dental Instruments
      Health Care
    • InspireMD to Announce Second Quarter 2025 Financial Results

      MIAMI, Fla., July 22, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that it will release its second quarter 2025 financial results on Tuesday, August 5, 2025. In conjunction with the release, InspireMD will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the live earnings call via telephone by dialing 1-800-579-2543 for domestic callers or 1-785-424-1789 for international callers. The live webinar may be accessed by visiting InspireMD's website or by registering below. A replay of

      7/22/25 7:00:00 AM ET
      $NSPR
      Medical/Dental Instruments
      Health Care
    • BSGM Engages CXG to Acquire FINRA/SEC-Registered Broker-Dealer to Expand Publicly Traded RWA Tokenization Operations

      Will Position Streamex as one of the first NASDAQ Listed SEC and FINRA Compliant Issuers of RWA Tokens in the U.S. BioSig Technologies, Inc. (NASDAQ:BSGM) ("BioSig"), which recently merged with Streamex Exchange Corporation ("Streamex") (together, "BSGM" or the "Company"), is excited to announce a critical step toward becoming one of the first fully regulated Real-World Asset ("RWA") tokenization companies trading on a major United States exchange: Streamex has engaged Compliance Exchange Group (CXG) to lead and manage the acquisition of a specific FINRA and SEC registered broker-dealer with licensed operations. This press release features multimedia. View the full release here: https://

      7/14/25 8:30:00 AM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $BSGM
    $BSX
    $NSPR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Fujimori Yoshiaki sold $310,378 worth of shares (2,901 units at $106.99), decreasing direct ownership by 58% to 2,081 units (SEC Form 4)

      4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)

      7/30/25 4:06:10 PM ET
      $BSX
      Medical/Dental Instruments
      Health Care
    • Director Ludwig Edward J sold $424,120 worth of shares (4,000 units at $106.03), decreasing direct ownership by 18% to 18,479 units (SEC Form 4)

      4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)

      7/28/25 4:10:19 PM ET
      $BSX
      Medical/Dental Instruments
      Health Care
    • Director Berman Michael exercised 61,248 in-the-money shares at a strike of $1.38 (SEC Form 4)

      4 - InspireMD, Inc. (0001433607) (Issuer)

      7/23/25 4:05:36 PM ET
      $NSPR
      Medical/Dental Instruments
      Health Care

    $BSGM
    $BSX
    $NSPR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP & Group Pres, Cardiology Fitzgerald Joseph Michael bought $4,515 worth of shares (50 units at $90.29), sold $1,799 worth of shares (20 units at $89.97), was granted 31,680 shares and covered exercise/tax liability with 14,447 shares, increasing direct ownership by 17% to 172,863 units (SEC Form 4)

      4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)

      2/13/25 4:32:41 PM ET
      $BSX
      Medical/Dental Instruments
      Health Care
    • Roubin Gary S bought $126,540 worth of shares (50,000 units at $2.53), increasing direct ownership by 13% to 438,902 units (SEC Form 4)

      4 - InspireMD, Inc. (0001433607) (Issuer)

      12/4/23 4:15:25 PM ET
      $NSPR
      Medical/Dental Instruments
      Health Care

    $BSGM
    $BSX
    $NSPR
    Leadership Updates

    Live Leadership Updates

    See more
    • BioSig & Streamex Appoint Defi Expert and Visionary, Russell Starr as Strategic Advisor

      BioSig Technologies, Inc. ("BioSig" or the "Company"), which recently merged with Streamex Exchange Corporation ("Streamex") (NASDAQ:BSGM), is pleased to announce the appointment of Russell Starr as Strategic Advisor to Streamex. Mr. Starr brings decades of experience in capital markets, business development, and transformative deal-making across, defi, traditional finance and emerging sectors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250711280588/en/ A former executive on Bay Street and respected entrepreneur and financier, Mr. Starr has built a reputation for navigating high-stakes financial transactions and guiding comp

      7/11/25 9:00:00 AM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Archimedes Vascular Announces Close of Series A Financing led by Sherpa Healthcare Partners and Appoints Raymond W. Cohen as Chairman of its Board of Directors

      BIRMINGHAM, Ala. and BEIJING, June 23, 2025 /PRNewswire/ -- Archimedes Vascular, Inc., a pre-clinical stage medical device company developing an implant for the treatment of severe hypertension announced a $2.2 million Series A financing led by Sherpa Healthcare Partners. In conjunction with the financing, also announced the appointment of veteran medical device executive, Raymond W. Cohen to serve as chairman of its board of directors. "We are grateful to Sherpa and Ray for recognizing the potential of this exciting project and providing the funding to facilitate execution of

      6/23/25 9:00:00 AM ET
      $BSX
      $KMTS
      Medical/Dental Instruments
      Health Care
    • BioSig & Streamex Appoint Parcl Co-Founders Trevor Bacon and Kellan Grenier as Strategic Advisors

      Los Angeles, CA & Vancouver, BC, June 09, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) ("BioSig"), which acquired Streamex Exchange Corporation as its wholly owned subsidiary ("Streamex") in May 2025, is pleased to announce the appointment of Trevor Bacon and Kellan Grenier, co-founders of Parcl, as Strategic Advisors. Together, they bring deep expertise at the intersection of decentralized finance, synthetic asset creation, and real-world asset tokenization. Parcl is a leading blockchain-native platform that enables users to gain exposure to real estate markets through synthetic, perpetual trading. Built on Solana, the platform offers users the ability to speculate on

      6/9/25 10:30:00 AM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $BSGM
    $BSX
    $NSPR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by InspireMD Inc.

      SC 13G - InspireMD, Inc. (0001433607) (Subject)

      12/4/24 4:31:06 PM ET
      $NSPR
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by InspireMD Inc.

      SC 13G/A - InspireMD, Inc. (0001433607) (Subject)

      11/14/24 6:35:20 PM ET
      $NSPR
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by BioSig Technologies Inc.

      SC 13G/A - BioSig Technologies, Inc. (0001530766) (Subject)

      11/14/24 3:58:00 PM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $BSGM
    $BSX
    $NSPR
    Financials

    Live finance-specific insights

    See more
    • Boston Scientific announces results for second quarter 2025

      MARLBOROUGH, Mass., July 23, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $5.061 billion during the second quarter of 2025, growing 22.8 percent on a reported basis, 21.6 percent on an operational1 basis and 17.4 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $797 million or $0.53 per share (EPS), compared to $324 million or $0.22 per share a year ago, and achieved adjusted3 EPS of $0.75 for the period, compared to $0.62 a year ago.

      7/23/25 6:30:00 AM ET
      $BSX
      Medical/Dental Instruments
      Health Care
    • InspireMD to Announce Second Quarter 2025 Financial Results

      MIAMI, Fla., July 22, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that it will release its second quarter 2025 financial results on Tuesday, August 5, 2025. In conjunction with the release, InspireMD will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the live earnings call via telephone by dialing 1-800-579-2543 for domestic callers or 1-785-424-1789 for international callers. The live webinar may be accessed by visiting InspireMD's website or by registering below. A replay of

      7/22/25 7:00:00 AM ET
      $NSPR
      Medical/Dental Instruments
      Health Care
    • Boston Scientific announces conference call discussing second quarter 2025 results

      MARLBOROUGH, Mass., July 1, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) will webcast its conference call discussing financial results and business highlights for the second quarter ended June 30, 2025, on Wednesday, July 23, 2025, at 8:00 a.m. ET. The call will be hosted by Mike Mahoney, chairman and chief executive officer, and Jon Monson, executive vice president and chief financial officer. The company will issue a news release announcing financial results for the second quarter on July 23 prior to the conference call. A live webcast and replay for the eve

      7/1/25 8:00:00 AM ET
      $BSX
      Medical/Dental Instruments
      Health Care